Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Effects of beta-glucuronidase inhibition in prostate cancer
EF 2023-24
Résumé
Prostate cancer (PCa) lacks meaningful biomarkers for early detection and desperately requires better therapeutics. The fact that PCa patients treated with standard of care androgen-deprivation therapy (ADT) invariably develop castration-resistant prostate cancer (CRPC) demonstrates that more effective treatment options are needed. Hence, we propose investigation of the role of the lysosomal enzyme beta-glucuronidase (?G) – a potential biomarker and/or drug target – in PCa. ?G reverses a detoxification process called glucuronidation, and acts on many glucuronide-containing compounds (i.e. drugs, steroids, chemicals) as well as glycosaminoglycans (GAGs): a cellular component implicated in cancer progression. Previous research has identified ?G as a novel biomarker and/or therapeutic target, however, the effects of ?G inhibition in PCa have not been investigated. Furthermore, existing ?G inhibitors are not effective. Our proposed research aims to accomplish the following: 1) Test a collection of novel ?G inhibitors in vitro, characterizing the kinetics of each compound and determining whether they have a killing effect in PCa cell lines, and 2) Use liquid-chromatography mass spectrometry (LC-MS) to characterize glucuronidation patterns of metabolites of interest in PCa patient serum and tissue lysates, as well as examine the effect of ?G inhibition on these glucuronidation patterns in vitro using our lead compound from Aim 1. The proposed research fulfills the need for investigation of novel PCa biomarkers and drug targets, and aims to explore an avenue that is still relatively uncharacterized and poorly understood.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505867
Name
Beletsky Maria J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effects of beta-glucuronidase inhibition in prostate cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Beta-Glucuronidase; Glucuronidation; Glycosaminoglycans; Prostate Cancer; Steroid Metabolism
Abstract
Prostate cancer (PCa) lacks meaningful biomarkers for early detection and desperately requires better therapeutics. The fact that PCa patients treated with standard of care androgen-deprivation therapy (ADT) invariably develop castration-resistant prostate cancer (CRPC) demonstrates that more effective treatment options are needed. Hence, we propose investigation of the role of the lysosomal enzyme beta-glucuronidase (?G) – a potential biomarker and/or drug target – in PCa. ?G reverses a detoxification process called glucuronidation, and acts on many glucuronide-containing compounds (i.e. drugs, steroids, chemicals) as well as glycosaminoglycans (GAGs): a cellular component implicated in cancer progression. Previous research has identified ?G as a novel biomarker and/or therapeutic target, however, the effects of ?G inhibition in PCa have not been investigated. Furthermore, existing ?G inhibitors are not effective. Our proposed research aims to accomplish the following: 1) Test a collection of novel ?G inhibitors in vitro, characterizing the kinetics of each compound and determining whether they have a killing effect in PCa cell lines, and 2) Use liquid-chromatography mass spectrometry (LC-MS) to characterize glucuronidation patterns of metabolites of interest in PCa patient serum and tissue lysates, as well as examine the effect of ?G inhibition on these glucuronidation patterns in vitro using our lead compound from Aim 1. The proposed research fulfills the need for investigation of novel PCa biomarkers and drug targets, and aims to explore an avenue that is still relatively uncharacterized and poorly understood.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beletsky, Maria J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~